Abstract 1441P
Background
The accurate detection of lymph node metastasis (LNM) in early gastric cancer (EGC) remains a challenge, conventional radical gastrectomy may not be warranted for EGC patients with a low LNM risk and a favorable prognosis. This study aims to construct a risk prediction model of lymph node metastasis based on clinicopathologic features, tumor budding, convolutional neural network, and machine learning in early gastric cancer.
Methods
Clinicopathological features and tumor budding (TB) were assessed using the image recognition software Qupath. There was a total of 1523471 patches, 260998 patches, and 166594 patches from three patient cohorts that were retrospectively analyzed. Convolutional neural networks (CNNs) were used for deep transfer learning to classify patches and extract features. LASSO regression and multiple machine learning algorithms were employed to combine CNN features with clinicopathological features. The risk prediction model was also verified in two independent validation cohorts.
Results
Among 200 patients, LNM incidence was 27.14% in the training cohort, 15.15% in the internal validation cohort, and 14.82% in the external validation cohort. Multivariate analysis identified pathological T stage and ITBCC-TB grade as independent LNM risk factors (p < 0.05). The Resnet152 CNN model demonstrated excellent performance with AUC values of 0.995, 0.988, and 0.965 in the training, internal validation, and external validation cohorts, respectively. The CNN-ML model using Gradient Boosting exhibited superior predictive capacity, with AUC values of 0.901 (95% CI 0.844-0.957), 0.871 (95% CI 0.726-0.999), and 0.804 (95% CI 0.555-0.999) in the training and two independent validation cohorts.
Conclusions
Pathological T stage and ITBCC-TB grade were identified as independent risk factors for LNM in EGC. The integration of clinicopathological features, image recognition, and deep transfer learning using CNNs resulted in a highly accurate predictive model for LNM in EGC. This model will provide valuable insights into the development of a more comprehensive and individualized approach to managing EGC, thereby improving the quality of care for affected patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1937P - Clinical characteristics and prognosis of pediatric patients with papillary thyroid carcinoma
Presenter: Junko Akaishi
Session: Poster session 18
1938P - Nomogram for predicting lung metastases in patients with papillary thyroid cancer under 55 years old
Presenter: Huiyun Yang
Session: Poster session 18
1939P - BrafV600E-induced cancer inflammation in a mouse model of thyroid tumorigenesis
Presenter: Sima Kumari
Session: Poster session 18
1940TiP - Sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory thyroid carcinoma and anaplastic thyroid carcinoma: The phase II SETHY, GETNE-T2318 trial design
Presenter: Alejandro Garcia Alvarez
Session: Poster session 18
1941TiP - Neoadjuvant pembrolizumab in high-risk thyroid cancer (NePenTHe)
Presenter: Claudia Leli
Session: Poster session 18
1924P - Efficacy and safety of lenvatinib in patients with chemotherapy-naive advanced or recurrent thymic carcinoma: A multicenter retrospective study
Presenter: Daisuke Hazama
Session: Poster session 18
1923P - Real-world management and outcome of thymic carcinomas in a tertiary German center
Presenter: Antonia Margineanu
Session: Poster session 18
1922P - Targeted resequencing designed specifically for thymic epithelial tumours confirmed the high prevalence of GTF2I mutations
Presenter: Iacopo Petrini
Session: Poster session 18
1921P - Molecular analysis of mesothelioma reveals mutations as prognostic biomarkers for patients treated with the combination of ipilimumab and nivolumab
Presenter: Angelica Rigutto
Session: Poster session 18
1920P - Multiomics analysis of malignant pleural mesothelioma and the effect of immune checkpoint inhibitors
Presenter: Akiko Tateishi
Session: Poster session 18